@article{ATM12785,
author = {Keunchil Park},
title = {Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study},
journal = {Annals of Translational Medicine},
volume = {4},
number = {23},
year = {2016},
keywords = {},
abstract = {We thank Professor Lee for his interest in our recent LUX-Lung 7 publication that assessed afatinib versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) (1). We agree that, in an ideal world, afatinib and gefitinib would have been compared in a Phase III trial with a formal hypothesis. However, given the lack of data available at the conception of LUX-Lung 7 (2010‒2011), we made the pragmatic decision to undertake an exploratory Phase IIb trial.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/12785}
}